161 related articles for article (PubMed ID: 11266232)
1. RSV disease--is there a role for prevention?
Lenney W
Respir Med; 2001 Mar; 95(3):170-2. PubMed ID: 11266232
[No Abstract] [Full Text] [Related]
2. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
Robinson JL
Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
[No Abstract] [Full Text] [Related]
3. Immunoprophylaxis of respiratory syncytial virus infection.
Simoes EA
Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia PJ; Malinoski FJ
Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
[No Abstract] [Full Text] [Related]
5. Palivizumab (synagis): counting "costs" and values.
Carter BS
Pediatrics; 2000 Nov; 106(5):1168-9. PubMed ID: 11185071
[No Abstract] [Full Text] [Related]
6. [Prevention of respiratory syncytial virus infections with palivizumab].
Ellingsen BB; Aase SA; Øymar K
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
[No Abstract] [Full Text] [Related]
7. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
[TBL] [Abstract][Full Text] [Related]
8. [Respiratory syncytial virus infections and preventive options].
Moll HA; de Groot R
Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
[No Abstract] [Full Text] [Related]
9. Respiratory syncytial virus market.
Storey S
Nat Rev Drug Discov; 2010 Jan; 9(1):15-6. PubMed ID: 20043025
[No Abstract] [Full Text] [Related]
10. Prevention and treatment of respiratory syncytial virus infections (for advances in pediatric infectious diseases).
DeVincenzo J
Adv Pediatr Infect Dis; 1997; 13():1-47. PubMed ID: 9544306
[No Abstract] [Full Text] [Related]
11. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
[No Abstract] [Full Text] [Related]
12. Prevention of respiratory syncytial virus infection in infants.
Handforth J; Sharland M; Friedland JS
BMJ; 2004 May; 328(7447):1026-7. PubMed ID: 15117767
[No Abstract] [Full Text] [Related]
13. Cost effectiveness of palivizumab in children with congenital heart disease in Germany.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):301-8. PubMed ID: 19811110
[TBL] [Abstract][Full Text] [Related]
14. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
McCormick J; Tubman R
Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567
[TBL] [Abstract][Full Text] [Related]
15. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
Mitchell I
South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
[No Abstract] [Full Text] [Related]
17. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
[No Abstract] [Full Text] [Related]
18. RSV infection and bronchiolitis: who qualifies for prevention?
Prescrire Int; 2000 Dec; 9(50):173. PubMed ID: 11475495
[TBL] [Abstract][Full Text] [Related]
19. [Current news about epidemiology of syncytial respiratory virus infection].
Palumbo E
Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965
[TBL] [Abstract][Full Text] [Related]
20. Prevention of respiratory syncytial virus infection in high risk infants.
Prince AM; Jacobs RF
J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
